We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Circulating Tumor Cells in Long-Term Cancer Survivors

By Biotechdaily staff writers
Posted on 22 Dec 2004
Researchers have found circulating tumor cells (CTCs) in long-term breast cancer survivors, who may have some innate mechanisms to keep the cancer from progressing. More...
The findings were reported in the December 2004 issue of Clinical Cancer Research.

The investigators collected blood from 36 women who had mastectomies and had been clinically cancer-free for at least seven years. Of those, 13 were found to have CTCs, but the number was low and remained low. Since CTCs are short-lived, they must constantly be replenished, possibly from tiny tumors somewhere in the body. CTCs were found in women up to 20 years after having a mastectomy, who have a very low risk of recurrence. After 20 years, the risk rises to 20% of survivors.

"Dormancy is a mysterious phenomenon that occurs in certain types of cancer,” said lead author Dr. Jonathan Uhr, professor in the Cancer Immunobiology Center at the University of Texas Southwestern Medical Center (Dallas, USA; www.utsouthwestern.edu). He said there appears to be a precise balance between tumor cell replication and cell death. Those women who stay healthy may have developed a way of keeping the size of the tumor cell population in check, making breast cancer a chronic illness in those patients.

The next step, according to Dr. Uhr, is to investigate the mechanisms for how the body and cancer cells peacefully coexist. The answers could reveal new ways to control cancer. "If patients at risk for impending relapse can be identified, it may be possible to prevent recurrence with appropriate therapy,” added Dr. Uhr.






Related Links:
U. Texas Southwestern

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.